Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment
- 2 July 2020
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 36 (7) , 566-573
Abstract
Barriers to sustainable virologic suppression (VS) of HIV-infected adolescents and young adults include drug resistance mutations (DRMs) and limited treatment options, which may impact the outcome of second-line antiretroviral therapy (ART). We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. We evaluated first-line nucleoside reverse transcriptase inhibitor (NRTI) susceptibility scores to first- and second-line regimens. Boosted protease inhibitor (bPI)-based ART was provided and viral load (VL) monitored for ≥48 weeks. Fisher's exact test was used to evaluate factors associated with VS on second-line regimens, defined as VL 1,000 ) or 50 ). The 74 participants on first-line ART had a median [interquartile range (IQR)] age of 18 (16–21) years and 42 (57%) were female. The mean (±standard deviation) duration on ART was 5.5 (±3.06) years and the median (IQR) log 10 VL was 4.26 (3.78–4.83) copies/mL. After switching to a second-line PI regimen, 88% suppressed to 50 ( p = .031). These 74 adolescents and young adults failing first-line ART demonstrated high levels (97%) of DRMs, despite enhanced adherence counseling. Switching to new NRTIs in second-line improved VS. With the widespread adoption of generic dolutegravir, lamivudine and tenofovir combinations in Africa, genotyping to determine NRTI susceptibility, may be warranted.Keywords
This publication has 54 references indexed in Scilit:
- Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South AfricaPLOS ONE, 2013
- Antiretroviral Drug Resistance Profiles and Response to Second-Line Therapy Among HIV Type 1-Infected Ugandan ChildrenAIDS Research and Human Retroviruses, 2013
- Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence dataBioinformatics, 2012
- Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility studyResearch in Social and Administrative Pharmacy, 2012
- Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over TimePLOS ONE, 2010
- The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical ImplicationsHIV Therapy, 2009
- Early Patterns of Adherence in Adolescents Initiating Highly Active Antiretrovial Therapy Predict Long-Term Adherence, Virologic, and Immunologic ControlAIDS Patient Care and STDs, 2009
- Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2008
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006
- HIV-1 viral load blips are of limited clinical significanceJournal of Antimicrobial Chemotherapy, 2006